Dark
Streaming/Mobile
OldĀ Site
Home
Products
Help
Contact Us
Your Account
System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:31:15 EDT Thu 10 Jul 2025
Quotes
Streaming/Mobile
Quick Quotes (x20)
Symbol Search
Company Search
Market Depth
US Options
Montreal Options
Foreign Exchange
Download Close Prices
Short History
Quotes Help
Charts
12 Month Chart
Advanced Chart
Live Intraday Chart
Live Historical Chart
Live Java Intraday Chart
Live Java Historical Chart
Charts Help
News
News Search
SEDAR Search
SEDAR Alerts
News Help
Indexes
Major Indexes
US incl Dow Jones
NASDAQ
S&P CME
PBOT - Phil Ex
TSX - Toronto
TSX-V - TSX Venture
Indexes Help
Portfolio
View Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Value Portfolio
All Portfolios
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Edit Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Chart Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Live Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
View Portfolio News
Daily Summary
Portfolio Help
Analytics
Exchange Statistics
Most Active
Live Most Active
Block Trades
Broker Trades
Halted Stocks
Dividends
Participants
Companies
Trade Workstation
Company Picker
Short Positions
Broker Codes
Analytics Help
Mutual Funds
Mutual Fund Search
Targeted Holder Search
SEDAR Fund Search
Mutual Fund Help
Enter Symbol
or Name
USA
CA
Quote
Chart
News
Closes
Depth
Forgot password?
Trouble logging in?
Login to Stockwatch
Z:LLY
- ELI LILLY AND COMPANY -
https://www.lilly.com
20:31:15 EDT
Sym-X
Bid - Ask
Last
Chg
%Ch
Vol
$Vol
#Tr
Open-Hi-Lo
Year Hi-Lo
Last Tr
News
Delay
LLY
- Z
9.0
790.21
·
790.56
5.0
790.54
+3.62
0.5
3,131.3
2,474,507
57,610
789.80
799.4922
786.43
972.53 677.0912
19:59:56
Jul 09
15 min
RT 2¢
Trade times are ET. News times are ET. Bid/ask/vol sizes in thousands.
Fundamentals
·
Holders
·
Trade Workstation
·
Market Depth
·
3 Month Closes
·
Technical Charts
1 yr
|
2 yr
|
3 yr
|
5 yr
|
10 yr
|
15 yr
|
20 yr
·
Live Charts
1 yr
|
1 day
·
1yr Bulletins
·
Historical
·
Options
·
Portfolio
Recent Trades - Last 10 of 57610
More trades...
Time ET
Ex
Price
Change
Volume
19:59:56
Z
790.40
3.48
1
19:59:54
Z
790.4999
3.5799
2
19:59:03
Z
790.50
3.58
7
19:58:36
Z
790.4999
3.5799
1
19:58:36
Z
790.4999
3.5799
4
19:58:03
Z
790.50
3.58
1
19:57:06
Z
790.40
3.48
4
19:56:52
Z
790.50
3.58
1
19:56:06
Z
790.40
3.48
1
19:55:14
Z
790.3636
3.4436
22
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
Recent Bulletins
News Releases
In The News
Other
Date ET
Symbol
Type
Headline
2025-07-09 06:45
U:LLY
News Release
200
FDA approves updated label for Lilly's Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer's disease
2025-06-23 11:37
U:LLY
News Release
200
Lilly declares third-quarter 2025 dividend
2025-06-22 14:31
U:LLY
News Release
200
Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials
2025-06-21 09:01
U:LLY
News Release
200
Lilly's oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of Medicine
2025-06-17 06:45
U:LLY
News Release
200
Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
2025-06-16 06:45
U:LLY
News Release
200
Lilly to offer all approved doses of Zepbound (tirzepatide) single-dose vials through LillyDirect Self Pay Pharmacy Solutions
2025-06-02 10:00
U:LLY
News Release
200
Lilly to participate in Goldman Sachs 46th Annual Global Health Care Conference
2025-06-02 08:00
U:LLY
News Release
200
Lilly presents first clinical data for its investigational, next-generation FRalpha targeting ADC in platinum-resistant ovarian cancer at the 2025 ASCO Annual Meeting
2025-05-29 17:00
U:LLY
News Release
200
Lilly announces details of presentations at American Diabetes Association's (ADA) 85th Scientific Sessions
2025-05-27 10:00
U:LLY
News Release
200
Lilly to expand its pain pipeline with acquisition of SiteOne Therapeutics
2025-05-22 17:05
U:LLY
News Release
200
Lilly announces details of presentations at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
2025-05-21 16:21
U:LLY
News Release
200
Lilly's Kisunla (donanemab) receives marketing authorization in Australia for the treatment of early symptomatic Alzheimer's disease
2025-05-11 18:01
U:LLY
News Release
200
Zepbound (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in complete SURMOUNT-5 results published in The New England Journal of Medicine
2025-05-09 08:00
U:LLY
News Release
200
Lilly plans to expand Purdue University collaboration with up to a $250 million investment to accelerate pharmaceutical innovation
2025-05-08 06:45
U:LLY
News Release
200
Lilly announces transitions in executive leadership
2025-05-05 12:47
U:LLY
News Release
200
Lilly declares second-quarter 2025 dividend
2025-05-02 10:00
U:LLY
News Release
200
Lilly to participate in Bank of America Securities 2025 Healthcare Conference
2025-05-01 06:45
U:LLY
News Release
200
Lilly reports first-quarter 2025 financial results and highlights pipeline momentum
2025-04-17 10:00
U:LLY
News Release
200
Lilly confirms date and conference call for first-quarter 2025 financial results announcement
2025-04-17 06:45
U:LLY
News Release
200
Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial